Tech Company Financing Transactions

Cleave Therapeutics Funding Round

Cleave Therapeutics, operating out of San Francisco, secured $12 million in investment from 5AM Ventures, Arcus Ventures and Astellas Venture Capital.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

135 Main St. 1145
San Francisco, CA 94105
USA

Phone

(415) 562-8117

Website

www.cleavetherapeutics.com

Email Address

[email protected]

Overview

Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative diseases. There is a growing body of evidence around inhibiting VCP to target cancer stress pathways with known biological relevance in cancer.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Amy Burroughs

        

Chief Operating Officer

Scott Harris

        

Browse more venture capital transactions:

Prev: 8/7/2019: Human Interest venture capital transaction
Next: 8/8/2019: C2FO venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary